FDA offers first guidance on stimulant use disorder drug development
Regulatory NewsMary Ellen Schneider
North AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesRegulatory NewsMary Ellen SchneiderNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States